<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmedpharm</journal-id><journal-title-group><journal-title xml:lang="ru">Фармация и фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacy &amp; Pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2307-9266</issn><issn pub-type="epub">2413-2241</issn><publisher><publisher-name>Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.19163/2307-9266-2017-5-6-532-542</article-id><article-id custom-type="elpub" pub-id-type="custom">pmedpharm-277</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ И БИОТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY AND BIOTECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>ИЗУЧЕНИЕ ТЕХНОЛОГИЧЕСКИХ СВОЙСТВ СУБСТАНЦИИ И БАЗОВОГО СОСТАВА ДЛЯ ПОЛУЧЕНИЯ ГОТОВОЙ ЛЕКАРСТВЕННОЙ ФОРМЫ ПРЕПАРАТА «БИОМАЙРИН»</article-title><trans-title-group xml:lang="en"><trans-title>STUDY OF TECHNOLOGICAL PROPERTIES OF SUBSTANCE AND BASIC COMPOSITION FOR OBTAINING THE DRUG PRODUCT OF “BIOMAYRIN”</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маматмусаева</surname><given-names>Н. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamatmusaeva</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маматмусаева Нилуфар Эркиновна – кандидат фармацевтических наук, старший научный сотрудник лаборатории химии полисахаридов.</p><p>100125, Ташкент, ул. Мирзо Улугбека, 83</p><p>ID: C20150626133628</p></bio><bio xml:lang="en"><p>Mamatmusaeva Nilufar Erkinovna – PhD (Pharmacy), Senior Researcher, Laboratory of Polysaccharide Chemistry.</p><p>83, Mirzo Ulugbek Str., Tashkent city, 100125</p></bio><email xlink:type="simple">erkinova81@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шомуратов</surname><given-names>Ш. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shomuratov</surname><given-names>Sh. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шомуратов Шавкат Абдуганиевич – кандидат химических наук, старший научный сотрудник лаборатории химии полисахаридов.</p><p>100125, Ташкент, ул. Мирзо Улугбека, 83</p><p>ID: C201406154030</p></bio><bio xml:lang="en"><p>Shomuratov Shavkat Abduganievich – PhD (Chemistry), Senior Researcher, Laboratory of Polysaccharide Chemistry.</p><p>83, Mirzo Ulugbek Str., Tashkent city, 100125</p></bio><email xlink:type="simple">shsha@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сагдуллаев</surname><given-names>Б. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Sagdullaev</surname><given-names>B. Т.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сагдуллаев Баходир Тахирович – доктор технических наук, старший научный сотрудник лаборатории химии полисахаридов.</p><p>100125, Ташкент, ул. Мирзо Улугбека, 83</p></bio><bio xml:lang="en"><p>Sagdullaev Bakhadir Takhirovich – PhD (Technique), Senior Researcher, Laboratory of Polysaccharide Chemistry.</p><p>83, Mirzo Ulugbek Str., Tashkent city, 100125</p></bio><email xlink:type="simple">bsagdullaev29@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тураев</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Turaev</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тураев Аббасхан Сабирханович – доктор химических наук, заместитель директора по научным вопросам института биоорганической химии Академии Наук.</p><p>100125, Ташкент, ул. Мирзо Улугбека, 83</p></bio><bio xml:lang="en"><p>Turaev Abbaskhan Sabirkhanovich – PhD (Chemistry), Deputy Director for Scientifi c Affairs.</p><p>83, Mirzo Ulugbek Str., Tashkent city, 100125</p></bio><email xlink:type="simple">abbaskhan@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт биоорганической химии Академии Наук</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Institute of Bioorganic Chemistry of the Academy of Sciences</institution><country>Uzbekistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>01</day><month>01</month><year>2018</year></pub-date><volume>5</volume><issue>6</issue><fpage>532</fpage><lpage>542</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Маматмусаева Н.Э., Шомуратов Ш.А., Сагдуллаев Б.Т., Тураев А.С., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Маматмусаева Н.Э., Шомуратов Ш.А., Сагдуллаев Б.Т., Тураев А.С.</copyright-holder><copyright-holder xml:lang="en">Mamatmusaeva N.E., Shomuratov S.A., Sagdullaev B.Т., Turaev A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmpharm.ru/jour/article/view/277">https://www.pharmpharm.ru/jour/article/view/277</self-uri><abstract><p>Применяемые в настоящее время для лечения туберкулеза низкомолекулярные синтетические лекарства высокотоксичные и не обладают способностью избирательно проникать в фагоциты, к тому же быстро выводятся из организма, не обеспечивая пролонгированного действия. Для решения существующей проблемы применены современные методы модифицирования свойств биологически активных соединений совместным синтезом антибиотика с высокомолекулярными соединениями путем включения в полимеры-носители противотуберкулезные препараты, что позволило целенаправленно изменить их физико-химические и медико-биологические свойства.</p><p>Цель работы – оценка технологических свойств субстанции комбинированного противотуберкулезного препарата «Биомайрин» и разработка готовой лекарственной формы препарата.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В качестве объекта исследования использована субстанция оригинального лекарственного препарата «Биомайрин», полученная на основе высокомолекулярных соединений и синтетических противотуберкулезных препаратов методом молекулярного конструирования.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Показаны результаты сопоставительного анализа технологических свойств субстанции биомайрин и приготовленных масс с добавлением различных антифрикционных веществ. Введение антифрикционных веществ улучшало технологические свойства субстанции. В результате величина угла естественного откоса снижалась с 42,7 до 31–39°, а сыпучесть возрастала до 2,6–3,6 г/с.</p></sec></abstract><trans-abstract xml:lang="en"><p>The low-molecular synthetic drugs, used for the treatment of tuberculosis nowadays, are highly toxic and do not have the ability to selectively penetrate into phagocytes; besides, they are quickly removed from the body without providing a prolonged action. To solve the existing problem, modern methods of modifying the properties of biologically active compounds by joint synthesis of antibiotic with high-molecular compounds, by incorporating antituberculosis drugs into the carrier polymers have been applied. These methods have made it possible to purposefully change their physical-chemical and medical-biological properties.</p><p>The aim of the work is to evaluate the technological properties of the substance of the combined anti-tuberculosis drug “Biomayrin” and to work out its drug product.</p><sec><title>Materials and methods</title><p>Materials and methods. The object of the study was the substance of the original medicinal preparation “Biomayrin”, obtained on the basis of high molecular compounds, and synthetic antituberculosis drugs by the molecular design method.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The results of the comparative analysis of technological properties of the biomayrin substance and the prepared capsular masses with the addition of various antifriction agents are shown in the article. The introduction of antifriction agents greatly improved the technological properties of the substance. As a result, the angle of the natural slope decreased from 42.7° to 31–39°, and the fl owability increased to 2.6–3.6 g/s.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>противотуберкулезные препараты</kwd><kwd>биомайрин</kwd><kwd>технологические свойства субстанции</kwd><kwd>антифрикционные вещества</kwd><kwd>твердая готовая лекарственная форма</kwd></kwd-group><kwd-group xml:lang="en"><kwd>anti-tuberculosis drugs</kwd><kwd>biomayrin</kwd><kwd>technological properties of the substance</kwd><kwd>antifriction substances</kwd><kwd>solid drug product</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO report 2016: Global tuberculosis report 2016. URL: http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf (дата обращения: 11.07.2017)</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO report 2016: Global tuberculosis report 2016 [Internet]. [cited 2017 Iul 11]. Available from: http://www.who.int/about/licensing/copyright_form/index. html.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Global report on surveillance and response «Multidrug and extensively drug resistant TB (M/XDR-TB)». WHO, 2010. P. 1–71. URL: http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf (дата обращения: 11.07.2017)</mixed-citation><mixed-citation xml:lang="en">Global report on surveillance and response «Multidrug and extensively drug resistant TB (M/XDRTB)» [Internet]. WHO, 2010. P. 1-71. [cited 2017 Iul 11]. Available from: http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Красносельских И.В., Щепочкина Ю.А., Гарасько Е.В. Капсульная форма – новый подход для лечения больных туберкулезом // Фармация. 2012. №7. С. 38–41.</mixed-citation><mixed-citation xml:lang="en">Krasnoselskih IV, Shepochkina YuA, Garasko EV. Kapsulnaya forma – novyj podhod dlya lecheniya bolnyh tuberkulezom [Capsule form – a new approach for the treatment of patients with tuberculosis]. Pharmacy. 2012; 7:38. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедева Н.О., Сухова Е.В. Формирование мотивации к лечению у больных туберкулезом легких // Проблемы туберкулеза и болезней легких. 2006. №12. С. 13–16.</mixed-citation><mixed-citation xml:lang="en">Lebedeva NO, Sukhova EV. Formirovanie motivacii k lecheniyu u bolnyh tuberkulezom legkih [Formation of motivation to the treatment of patients with pulmonary tuberculosis]. Tuberculosis and Lung Diseases. 2006;12:13–6. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Регистр лекарственных средств (РЛС). 2017. URL: http://www.rlsnet.ru (дата обращения: 13.07.2017)</mixed-citation><mixed-citation xml:lang="en">Registr lekarstvennyh sredstv. [Russian register of medicines]. [Internet]. 2017. 25-edition. [cited 2017 Iul 13]. Available from: http://www.rlsnet.ru. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Магхраби Ж., Можокина Г.Н., Аляутдин Р.Н, Оганесян Е.А., Елистратова Н.А. Разработка и фармакологическое изучение наносамальных форм некоторых противотуберкулезных препаратов // Российский медицинский журнал. №2. 2012. С. 33–35.</mixed-citation><mixed-citation xml:lang="en">Maghrabi J, Mojokina GN, Alyautdin RN, Oganesyan EA, Yelistratova NA. Razrabotka i farmakologicheskoe izuchenie nanosamalnyh form nekotoryh protivotuberkuleznyh preparatov [Development and pharmacological study of nanoparticle forms of some antituberculosis drugs]. Rossijskij medicinskij zhurnal. 2012;2:33–5. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kaur K., Gupta A., Narang R.K., Murthy R.S. Novel drug delivery systems: desired feat for tuberculosis // J. Adv. Pharm. Technol. Res. 2010. Vol. 1. No. 2. P. 145–163.</mixed-citation><mixed-citation xml:lang="en">Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery systems: desired feat for tuberculosis. J. Adv. Pharm. Technol. Res. 2010;1(2):145–63.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tsubota N., Tanimukai S. A clinical experience of rifampicin suppository for the treatment of pulmonary tuberculosis // Kekkaku. 2015. Vol. 90. No. 6. P. 543–547.</mixed-citation><mixed-citation xml:lang="en">Tsubota N, Tanimukai S. A clinical experience of rifampicin suppository for the treatment of pulmonary tuberculosis. Kekkaku. 2015. Jun; 90(6):543–7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shegokar Ranjita A., Shaal L., Mitri K. Present Status of Nanoplasticle Researche for Treatment of Tuberculosis // J. Pharm. Pharm. Sci. 2011.Vol. 14. No. 1. P. 100–116.</mixed-citation><mixed-citation xml:lang="en">Shegokar Ranjita A, Shaal L, Mitri K. Present Status of Nanoplasticle Researche for Treatment of Tuberculosis. J. Pharm. Pharm. Sci. 2011;14(1):100–16.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sabitha P., Ratna J.V., Reddy K.R. Design and evaluation of controlled release chitosan-calcium alginate microcapsules of antitubercular drugs for oral use // Int. J. Chem. Technol. Res. 2010.Vol. 2. No. 1. P. 88–98.</mixed-citation><mixed-citation xml:lang="en">Sabitha P, Ratna JV, Reddy KR. Design and evaluation of controlled release chitosan-calcium alginate microcapsules of antitubercular drugs for oral use. Int. J. Chem. Technol. Res. 2010;2(1):88–98.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Шомуратов Ш.А., Ахмедов О.Р., Тураев А.С. Комбинированное противотуберкулезное средство пролонгированного действия // Заявка на патент IAP 20160219 от 07/06/2016 г.</mixed-citation><mixed-citation xml:lang="en">Shomurotov ShA, Akhmedov OR, Turaev AS. Kombinirovannoe protivotuberkuleznoe sredstvo prolongirovannogo dejstviya [The combined antituberculosis drugs of prolonged action]. The patent application IAP 20160219 07.06.2016. Uzbekistan.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шомуратов Ш.А., Ахмедов О.Р., Тураев А.С. Количественное определение действующих веществ в противотуберкулёзном препарате биомайрин // Фармацевтический вестник Узбекистана. Ташкент. 2013. №1. С. 45–49.</mixed-citation><mixed-citation xml:lang="en">Shomurotov ShA, Ahmedov OR, Turaev AS. Kolichestvennoe opredelenie dejstvuyushchih veshchestv v protivotuberkuleznom preparate biomajrin [Quantitative determination of active ingredients in antituberculosis preparation biomayrin]. Farmacevticheskij vestnik Uzbekistana. Тashkent. 2013;1:45–9. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная Фармакопея Российской Федерации. XIII издание, том II, Москва, 2015. URL: http://www.femb.ru/feml (дата обращения: 11.07.2017)</mixed-citation><mixed-citation xml:lang="en">Gosudarstvennaya Farmakopeya Rossijskoj Federacii [State Pharmacopoeia of Russian Federation]. [Internet]. XIII edition. Moscow, 2015(Pt 2):215. [cited 2017 Iul 11]. Available from: http://www.femb.ru/feml. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Шомуротов Ш.А., Мамадуллаев Г., Тураев А.С. Медико-биологические свойства полисахаридных комплексов изониазида и этамбутола // Биомедицинская химия. Ташкент. 2016. Т. 62. №1. С.45-49. DOI: 10.18097/PBMC20166201045</mixed-citation><mixed-citation xml:lang="en">Shomurotov ShA, Mamadullaev G, Turaev AS. Mediko-biologicheskie svojstva polisaharidnyh kompleksov izoniazida i etambutola [Medical and biological properties of polysaccharide complexes isoniazid and ethambutol]. Biomedicinskaya khimiya. Taskent. 2016; 62(1):45-9. DOI: 10.18097/PBMC20166201045. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Емшанова С.В., Садчикова Н.П., Зуев А.П. О контроле размера и формы частиц лекарственных веществ // Химико-фармацевтический журнал. 2007. Т. 41. №1. С. 41–49.</mixed-citation><mixed-citation xml:lang="en">Yemshanova SV, Sadchikova NP, Zuev AP. O kontrole razmera i formy chastic lekarstvennyh veshchestv [On the control the size and shape of particles of drugs]. Pharmaceutical Chemistry Journal. 2007;41(1):41 – 9. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Anil Kumar K.N., Basu Ray S., Nagaraja V., Ashok M.R. Encapsulation and release of rifampicin using poly (vinyl pyrrolidone) – poly (methacrylic acid) polyelectrolyte capsules // Materials Science and Engineering. Vol. 29. No 8. 2009. P. 2508–2513. DOI:10.1016/j.msec.2009.07.019</mixed-citation><mixed-citation xml:lang="en">Anil Kumar KN, Basu Ray S, Nagaraja V, Ashok MR. Encapsulation and release of rifampicin using poly (vinyl pyrrolidone) – poly (methacrylic acid) polyelectrolyte capsules. Materials Science and Engineering. 2009;29(8):2508–13. DOI:10.1016/j.msec.2009.07.019</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Panchagnula R., Agrawal S., Ashokraj Y., Varma M., Sateesh K., Bhardwaj V., Bedi S., Gulati I., Parmar J., Kaul C.L., Blomberg B., Fourie B., Roscigno G., Wire R., Laing R., Evans P., Moore T. Fixed – dose comdinations for tuderculosis: Lessons learned from a clinical, formulation and regulatory perspective // Methods Find Exp Clin Pharmacol. 2004. Vol. 26. No. 9. P. 703-721. DOI: 10.1358/mf.2004.26.9.872568</mixed-citation><mixed-citation xml:lang="en">Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscigno G, Wire R, Laing R, Evans P, Moore T. Fixed – dose comdinations for tuderculosis: Lessons learned from a clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol. 2004;26(9):703–21. DOI: 10.1358/mf.2004.26.9.872568</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Емшанова С.В., Абрамович Р.А., Потанина О.Г. Влияние формы и размера частиц субстанций на качество готовых лекарственных средств // Научно-производственный журнал. 2014. № 2(7). C. 50–63.</mixed-citation><mixed-citation xml:lang="en">Yemshanova SV, Abramovich RA, Potanina OG. Vliyanie formy i razmera chastic substancij na kachestvo gotovyh lekarstvennyh sredstv [Effect of the shape and size of the particles of substances on the quality of fi nished medicaments]. Research &amp; Production Journal. 2014;2(7):50–63. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Фармацевтическая технология. Твердые лекарственные формы. Учебное пособие / под редакцией проф. Кедика С.А., Москва. 2011. 661 с.</mixed-citation><mixed-citation xml:lang="en">Farmacevticheskaya tekhnologiya. Tverdye lekarstvennye formy Uchebnoe posobie [Pharmaceutical of technology. Solid dosage forms. Tutorial]. Professor Kedik SA, editor. Moscow, 2011. 661 p. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Шаблакова А.С., Петров А.Ю., Уломский Е.Н. Значимые технологические свойства субстанции лекарственного вещества // Вестник уральской медицинской академической науки. 2011. №3/1(35). С. 91.</mixed-citation><mixed-citation xml:lang="en">Shablakova AS, Petrov AYu, Ulomskiy EN. Znachimye tekhnologicheskie svojstva substancii lekarstvennogo veshchestva [Signifi cant technological properties of the drug substance]. Journal of Ural Medical Academic Science. 2011;3/1(35):91. Russian.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
